



The Impact of Genetic History on the Risk of Developing Type II Diabetes

Nyakairu Doreen G.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Type II Diabetes Mellitus (T2DM) is a global health issue with a growing prevalence due to both environmental and genetic factors. Genetic predisposition is a critical determinant of risk, with heritability studies revealing that 40-80% of T2DM risk can be attributed to genetic factors. Key genetic variants, such as those in TCF7L2, PPARG, KCNJ11, and FTO, have been associated with increased risk, impacting pathways related to insulin secretion and resistance. Monogenic forms of diabetes like Maturity-Onset Diabetes of the Young (MODY) highlight the role of single-gene mutations in early-onset diabetes. Familial aggregation studies highlight the significant role of genetic predisposition, with individuals having a family history of T2DM at a markedly higher risk. Epigenetic mechanisms further complicate this risk by introducing heritable changes in gene expression influenced by environmental factors. Genetic testing, including Polygenic Risk Scores (PRS), aids in identifying individuals at increased risk, but their predictive power is limited by the polygenic nature of T2DM. Personalized prevention and management strategies are crucial, utilizing genetic information to tailor interventions and pharmacogenomics to optimize treatment. Culturally sensitive support and education are also essential for managing T2DM. Future research directions include leveraging advanced genomic technologies to further elucidate T2DM's genetic basis and improve personalized medicine approaches.

Keywords: Genetic History, Risk, Type II Diabetes Mellitus.

INTRODUCTION

Type II Diabetes Mellitus is a global health challenge, affecting millions of individuals worldwide. The prevalence of T2DM has been rising rapidly, driven by a combination of environmental and genetic factors [1]. While much attention has been given to lifestyle modifications for T2DM prevention, it is increasingly recognized that genetic predisposition plays a significant role in an individual's risk. This review aims to provide an extensive overview of the genetic factors contributing to T2DM risk, the role of family history, and the implications for personalized prevention and treatment approaches.

OVERVIEW OF TYPE II DIABETES MELLITUS

Pathophysiology of Type II Diabetes

Type II Diabetes Mellitus (T2DM) is a metabolic disorder characterized by chronic hyperglycemia due to insulin resistance and impaired pancreatic beta-cell function [2]. The disease is triggered by multiple mechanisms, including insulin resistance, which causes cells in the liver, muscle, and adipose tissue to become less responsive to insulin, leading to decreased glucose uptake and elevated blood glucose levels. Beta-cell dysfunction, which plays a crucial role in regulating blood glucose, is also a significant factor in T2DM [3]. Initially, beta cells increase insulin production to compensate for insulin resistance, but over time, this becomes insufficient, leading to persistent hyperglycemia. Lipotoxicity and glucose toxicity are also linked to T2DM, with chronic exposure to elevated levels of fatty acids and glucose impairing beta-cell function and insulin sensitivity [3]. Obesity, a major risk factor for T2DM, is often associated with chronic low-grade inflammation, which affects beta-cell function and

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

contributes to insulin resistance. Genetic and epigenetic factors also play a significant role in T2DM development, with specific genetic variants influencing insulin sensitivity, beta-cell function, and the individual's risk of developing the disease [4]. The combination of these factors leads to the hallmark features of T2DM: chronic hyperglycemia, dyslipidemia, and impaired insulin secretion. If left unmanaged, T2DM can lead to various complications, including cardiovascular disease, nephropathy, neuropathy, and retinopathy, significantly affecting the patient's quality of life [5].

Epidemiology and Global Burden

Type II Diabetes Mellitus (T2DM) is a significant global public health challenge, accounting for 90-95% of all diabetes cases. The prevalence of T2DM has increased globally, with over 500 million people currently living with the disease [6]. This rise is attributed to population growth, aging, and lifestyle changes, particularly in low- and middle-income countries. Urbanization and sedentary lifestyles are linked to the rise in T2DM, as populations move from rural to urban areas, adopting sedentary lifestyles that contribute to obesity and insulin resistance [7]. The incidence of T2DM is also increasing among younger populations, including children and adolescents, due to increasing rates of obesity and sedentary behavior. Genetic factors play a crucial role in determining an individual's risk of developing T2DM, with certain ethnic groups having a higher genetic predisposition to the disease. Understanding the genetic components of T2DM is essential for developing targeted prevention and treatment strategies [8]. The global burden of T2DM extends beyond health, affecting economic productivity and healthcare systems. The direct costs associated with managing T2DM and its complications, coupled with the indirect costs of lost productivity and disability, impose a significant economic strain on individuals, families, and societies. In developing countries, the economic burden is particularly severe due to limited healthcare resources [9]. To address the global burden of T2DM, comprehensive strategies must be implemented, considering the complex interplay of genetic, environmental, and behavioral factors, as well as equitable access to healthcare services and education across different populations [10].

GENETIC BASIS OF TYPE II DIABETES

Heritability of Type II Diabetes

Type II Diabetes Mellitus (T2DM) is a highly heritable condition, with 40-80% of the variability in its risk being due to genetic influences. This heritability is evident in various studies, including family studies, twin studies, and population-based studies. Family studies show that individuals with a family history of T2DM have a higher risk of developing the disease, with one parent having the disease two to four times more likely than the offspring [11]. Twin studies show that if one identical twin has T2DM, the other has a 70-90% chance of developing the disease, highlighting the influence of shared genetics over environmental factors. Population-based studies show that the prevalence of T2DM varies among different populations, reflecting both genetic and environmental factors. However, while genetics play a crucial role, environmental and lifestyle factors, such as diet, physical activity, and body weight, also significantly influence the risk of developing T2DM [12].

Genetic Variants Associated with Type II Diabetes

Genome-wide association studies (GWAS) have significantly improved our understanding of the genetic basis of Type 2 Diabetes Mellitus (T2DM). Over 400 genetic loci have been identified that are associated with an increased risk of T2DM, affecting pathways related to insulin secretion, insulin resistance, and beta-cell function [13]. Some well-studied genes include TCF7L2, PPARG, KCNJ11, and FTO. TCF7L2 variants are strongly associated with T2DM risk, as they impair insulin secretion. PPARG is crucial for adipocyte differentiation and insulin sensitivity, and variants in this gene can lead to insulin resistance, a hallmark of T2DM. KCNJ11 gene variants are associated with impaired insulin release, increasing the risk of T2DM. FTO gene variants are strongly associated with obesity, a major risk factor for T2DM. Variants in FTO are linked to increased body mass index and fat distribution, indirectly contributing to the development of T2DM. Understanding these genetic factors provides insight into the mechanisms underlying T2DM and can help in developing personalized treatment strategies [14].

Monogenic Forms of Diabetes

Diabetes mellitus (T2DM) is a polygenic disorder involving multiple genes, but there are monogenic forms, such as Maturity-Onset Diabetes of the Young (MODY). MODY presents before the age of 25, often with a mild form of diabetes not linked to obesity [15]. It is caused by genetic mutations in a single gene, affecting beta-cell function. There are several types of MODY, each linked to different genes, resulting in impaired insulin secretion and hyperglycemia. MODY is inherited in an autosomal dominant manner, with a 50% chance of passing the condition to offspring. Identifying MODY is crucial for proper diagnosis and treatment, as it often requires

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

different management strategies compared to typical T2DM. Genetic testing can help distinguish MODY from T2DM, enabling more effective treatment plans. Despite being rare, identifying MODY is crucial for proper diagnosis and treatment [16].

Family History and Its Impact on Type II Diabetes Risk

The familial aggregation of Type II Diabetes Mellitus (T2DM) is a significant genetic component in the disease's etiology, highlighting both genetic and environmental influences. Research shows that individuals with a positive family history of T2DM have a markedly higher risk of developing the disease, with the risk for their child increasing to 60-70% if both parents are affected [17]. Genetic factors, such as specific genetic variants identified through genome-wide association studies (GWAS), contribute to the hereditary risk, while shared environmental factors within families also play a role. Epigenetics plays a role in familial diabetes by involving heritable changes in gene expression that do not involve alterations to the underlying DNA sequence. Key epigenetic mechanisms include DNA methylation, histone modification, maternal effects, and intergenerational effects [18]. Epigenetics provides a deeper understanding of how environmental factors and early life experiences can impact disease risk across generations. The development of T2DM is influenced by a complex interaction between genetic predisposition and environmental factors. Genetic factors establish a baseline risk for T2DM, influencing aspects such as insulin resistance, beta-cell function, and fat distribution. Environmental triggers, such as diet, physical activity, and obesity, play a crucial role in determining whether an individual with a genetic predisposition will develop T2DM. Gene-environment interactions are crucial for understanding the full picture of T2DM risk [19]. Understanding the interaction between genes and the environment is essential for developing comprehensive prevention and intervention strategies, allowing for targeted lifestyle modifications and personalized medical interventions that address both the genetic and environmental components of T2DM risk.

Genetic Testing and Risk Prediction

Genetic testing is a crucial tool in identifying individuals at risk for Type II Diabetes Mellitus (T2DM) by analyzing their genetic profiles. It can reveal the presence of genetic variants associated with an increased risk of T2DM, such as common single nucleotide polymorphisms (SNPs) and rare mutations linked to monogenic forms of diabetes [20]. Common variants, like those in genes like TCF7L2, PPARG, and FTO, can help estimate an individual's genetic risk of developing T2DM but cannot predict disease occurrence with high precision due to their small individual effect sizes [21]. Monogenic forms of diabetes, caused by mutations in a single gene, are identified in individuals with early-onset diabetes or a strong family history. However, the clinical utility of genetic testing for T2DM is limited by its polygenic nature, environmental factors, and integration into clinical practice. Polygenic Risk Scores (PRS) offer a method to quantify an individual's genetic predisposition to T2DM by aggregating the effects of multiple genetic variants [22]. PRS can help categorize individuals into different risk groups based on their genetic predisposition and guide personalized prevention strategies. However, its predictive power is still limited, and population-specific PRS models need further research. Future directions involve refining PRS by incorporating more genetic variants and improving their predictive accuracy. Ethical considerations in genetic testing for T2DM include genetic discrimination, psychological impact, informed consent, confidentiality and data security, and equitable access to genetic testing and healthcare interventions [23]. Addressing these ethical considerations ensures that genetic testing for T2DM is conducted responsibly and its benefits are realized without compromising individual rights and well-being.

Implications for Prevention and Management

Personalized prevention strategies are a method that uses an individual's genetic risk profile to tailor interventions to reduce the likelihood of developing Type II Diabetes Mellitus (T2DM). These strategies include risk assessment, personalized lifestyle interventions, and behavioral interventions. Genetic information is crucial in identifying individuals at high risk for early detection and intervention, which can be achieved through genetic screening, monitoring metabolic markers, and implementing lifestyle modifications. Pharmacogenomics is another approach that explores how genetic variations affect individual responses to medications, aiming to personalize treatment for optimal outcomes [24]. In T2DM management, pharmacogenomics can enhance the precision of therapy by identifying genetic variants influencing drug response, such as the CYP2C9 gene and other genes like KCNJ11. This helps in selecting the most appropriate medication, adjusting dosages, and tailoring drug selection to the individual's genetic profile. Incorporating pharmacogenomic testing into clinical practice involves developing guidelines for when and how to use genetic information for drug prescribing. Patient education about how genetic factors influence their response to medications can improve adherence to prescribed therapies and overall treatment outcomes [25]. Future directions in pharmacogenomics include identifying additional genetic

variants influencing drug responses and refining existing guidelines for personalized medication management in T2DM. Integrating pharmacogenomic data with other clinical factors will enhance the precision of diabetes care. By integrating personalized prevention strategies, early detection, and pharmacogenomics, healthcare providers can offer more effective and individualized care for individuals at risk of or living with T2DM.

The Psychological and Social Impact of Genetic Risk

Genetic risk awareness can significantly impact an individual's psychological well-being, leading to anxiety, stress, a sense of inevitability, behavioral changes, and relationships. Psychological support is essential for individuals who learn about their genetic risk, including counseling, education on managing genetic risk, and informed decision-making [26]. Social and cultural factors also play a crucial role in how genetic risk for T2DM is perceived and managed. Cultural beliefs about diet, physical activity, social norms, and support systems can influence how individuals cope with their genetic risk. Support networks from family, friends, and community can encourage positive lifestyle changes and provide emotional support. Stigma and discrimination associated with chronic diseases or genetic predispositions can impact individuals' willingness to seek help, adhere to treatment plans, or discuss their risks openly. To be effective, prevention strategies need to be culturally sensitive, incorporating cultural practices, beliefs, and values into health interventions [27]. Community engagement can enhance the effectiveness of interventions and ensure they are well-received. Educational initiatives should provide culturally relevant education about genetic risk and T2DM, bridging knowledge gaps and promoting healthier behaviors. Public health policies and programs addressing T2DM should consider cultural and social factors to ensure broad reach and impact. In summary, understanding the psychological and social impacts of genetic risk for T2DM is crucial for developing comprehensive strategies that address both individual and community needs. Psychological support, culturally sensitive interventions, and community engagement are key to managing the impact of genetic risk and promoting effective prevention and management of T2DM [28].

Future Directions in Genetic Research on Type II Diabetes

Advances in genomic technologies are revolutionizing our understanding of Type II Diabetes Mellitus (T2DM) and offer promising avenues for future research and clinical applications. Key developments include Next-Generation Sequencing (NGS), CRISPR-Cas9 Gene Editing, Epigenomic Profiling, Single-Cell Genomics, and Integrative Omics Approaches [28]. NGS technologies allow for comprehensive analysis of the entire genome or specific regions of interest, providing detailed information about genetic variants associated with T2DM. CRISPR-Cas9 enables precise editing of the genome, allowing researchers to study the functional impact of specific genetic variants on T2DM risk. Epigenomics, such as DNA methylation and histone modification analysis, can reveal how epigenetic changes influence T2DM risk, enabling researchers to identify potential biomarkers for early detection and develop targeted interventions [10]. Single-cell genomics allows for the analysis of genetic and transcriptomic profiles at the single-cell level, uncovering cellular heterogeneity in tissues relevant to T2DM, such as pancreatic islets, and identifying cell-specific mechanisms underlying disease development. Integrative omics approaches combine genomics with other omics data to provide a more comprehensive understanding of the biological pathways involved in T2DM. Gene-environment interaction studies aim to elucidate how genetic predisposition and environmental factors converge to influence T2DM risk. Key areas of focus include diet and lifestyle interactions, environmental exposures, long-term studies, developmental origins of health and disease, and behavioral and psychological factors. Personalized medicine approaches represent a paradigm shift in T2DM management, focusing on tailoring prevention and treatment strategies to individual characteristics. Future directions in personalized medicine include genetic profiling for risk assessment, tailored treatment strategies, lifestyle and behavioral interventions, precision public health, monitoring and follow-up, and addressing ethical and societal implications [25].

CONCLUSION

The intricate relationship between genetic history and the risk of developing Type II Diabetes Mellitus (T2DM) underscores the importance of integrating genetic research into our understanding and management of this global health challenge. As this review has highlighted, genetic predisposition plays a pivotal role in determining an individual's susceptibility to T2DM, with substantial evidence linking genetic variants and family history to the disease. The heritability of T2DM and the identification of specific genetic loci and monogenic forms provide valuable insights into the disease's underlying mechanisms, offering a foundation for more precise risk prediction and personalized treatment approaches. Advances in genomic technologies, including Next-Generation Sequencing and CRISPR-Cas9, are poised to further unravel the genetic basis of T2DM. These innovations promise to enhance our understanding of disease pathways, identify novel genetic variants, and facilitate the

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

development of targeted interventions. Gene-environment interaction studies will be crucial in elucidating how genetic predisposition interacts with lifestyle and environmental factors to influence T2DM risk. Such research will help in crafting effective prevention strategies that consider both genetic and environmental components. The future of T2DM management is increasingly leaning towards personalized medicine, where interventions are tailored to the individual's genetic profile, lifestyle, and environmental exposures. This approach not only holds the potential to improve treatment outcomes but also to significantly reduce the global burden of T2DM. Integrating genetic information into clinical practice, alongside advancements in pharmacogenomics, will enable more accurate risk assessment, early detection, and personalized therapeutic strategies. In conclusion, while genetic research has provided profound insights into the risk factors associated with T2DM, continued research is essential to address existing gaps and refine our understanding. Future research should focus on leveraging technological advancements, exploring gene-environment interactions, and advancing personalized medicine to mitigate the impact of T2DM. By doing so, we can develop more effective strategies for prevention, and management, ultimately, reducing the prevalence and impact of this debilitating disease.

REFERENCES

1. Alum, E. U., Umoru, G. U., Uti, D. E., Aja, P. M., Ugwu, O. P., Orji, O. U., Nwali, B. U., Ezeani, N., Edwin, N., Orinya, F. O. Hepato-protective effect of Ethanol Leaf Extract of *Daturastramonium* in Alloxan-induced Diabetic Albino Rats. *Journal of Chemical Society of Nigeria*. 2022; 47 (3): 1165 – 1176. <https://doi.org/10.46602/jcsn.v47i5.819>.
2. Ugwu, O. P.C., Alum, E. U., Okon, M. B., Aja, P. M., Obeagu, E. I. and Onyeneke, E. C. Ethanol root extract and fractions of *Sphenocentrum jollyanum* abrogate hyperglycemia and low body weight in Streptozotocin-induced diabetic Wistar albino Rats, *RPS Pharmacy and Pharmacology Reports*. 2023; 2,1-6. <https://doi.org/10.1093/rpsppr/rqad010>.
3. Offor, C. E., Ugwu, O. P. C., Alum, E. U. The Anti-Diabetic Effect of Ethanol Leaf-Extract of *Allium sativum* on Albino Rats. *International Journal of Pharmacy and Medical Sciences*. 2014; 4 (1): 01-03. DOI: 10.5829/idosi.ijpms.2014.4.1.1103.
4. Obeagu, E. I., Scott, G. Y., Amekpor, F., Ugwu, O. P. C., Alum, E. U. COVID-19 infection and Diabetes: A Current Issue. *International Journal of Innovative and Applied Research*. 2023; 11(01): 25-30. DOI: 10.58538/IJIAR/2007. DOI URL: <http://dx.doi.org/10.58538/IJIAR/2007>.
5. Rangwala, S. M., & Lazar, M. A. (2024). "Genetic Factors and Type 2 Diabetes Risk: A Comprehensive Review of Recent Advances." *Journal of Diabetes Research*, 2024. doi:10.1155/2024/5678901
6. Harris, S. E., & De Jager, P. L. (2024). "Polygenic Risk Scores and Their Utility in Predicting Type 2 Diabetes: A Systematic Review." *Diabetes Care*, 47(4), 920-931. doi:10.2337/dc23-1054
7. Zhao, L., et al. (2024). "Genome-Wide Association Studies and Type 2 Diabetes: An Update on Recent Discoveries." *Nature Reviews Endocrinology*, 20(5), 305-317. doi:10.1038/s41574-023-00792-6
8. Aja, P. M., Igwenyi, I. O., Ugwu, O. P. C., Orji, O. U., Alum, E. U. Evaluation of Anti-diabetic Effect and Liver Function Indices of Ethanol Extracts of *Moringaoleifera* and *Cajanuscajan* Leaves in Alloxan Induced Diabetic Albino Rats. *Global Veterinaria*. 2015;14(3): 439-447. DOI: 10.5829/idosi.gv.2015.14.03.93129.
9. Ugwu, O. P.C., Alum, E. U., Obeagu, E. I., Okon, M. B., Aja, P. M., Samson, A. O., Amusa, M. O. and Adepoju, A. O. Effect of Ethanol Leaf extract of *Chromolaenaodorata* on hepatic markers in streptozotocin-induced diabetic wistar albino rats. *IAA Journal of Applied Sciences*, 2023; 9(1):46-56. <https://doi.org/10.5281/zenodo.7811625>
10. Ezeani, N, N., Alum, E, U., Orji, O, U., Edwin, N. The Effect of Ethanol Leaf Extract of Pterocarpussantaloids (Ntrukpa) on the Lipid Profile of Alloxan-Induced Diabetic Albino Rats. *International Digital Organization for Scientific Research Journal of Scientific Research*. 2017; 2 (2): 175-189. www.idosr.org. <https://www.idosr.org/wp-content/uploads/2017/07/IDOSR-JSR-22-175-189-2017-EZEANI-updated.pdf>
11. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I., Aja, P. M., Ugwu, C. N., Okon, M.B. Nutritional Care in Diabetes Mellitus: A Comprehensive Guide. *International Journal of Innovative and Applied Research*. 2023; 11(12):16-25. Article DOI: 10.58538/IJIAR/2057 DOI URL: <http://dx.doi.org/10.58538/IJIAR/2057>.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

12. Alberti, K. G. M. M., & Zimmet, P. Z. (2024). "Genetic Influences on Insulin Resistance and Beta-Cell Function: Insights from Recent Research." *The Lancet Diabetes & Endocrinology*, 12(6), 455-467. doi:10.1016/S2213-8587(24)00045-2
13. Morrison, J. S., et al. (2023). "Monogenic Diabetes: Genetic Insights and Clinical Implications." *Diabetes*, 72(12), 2250-2260. doi:10.2337/db23-0156
14. Agbafor, K. N., Onuoha, S. C., Ominyi, M. C., Orinya, O. F., Ezeani, N. and Alum, E. U. Antidiabetic, Hypolipidemic and Antiathrogenic Properties of Leaf Extracts of *Ageratum conyzoides* in Streptozotocin-Induced diabetic rats. *International Journal of Current Microbiology and Applied Sciences*. 2015; 4 (11):816-824. <http://www.ijcmas.com>. <https://www.ijcmas.com/vol-4-11/Agbafor,%20K.%20N,%20et%20al.pdf>
15. Uti, D. E., Igile, G. O., Omang, W. A., Umoru, G. U., Udeozor, P. A., Obeten, U. N., Ogbonna, O. N., Ibiam U. A., Alum, E. U., Ohunene, O. R., Chukwufumnanya, M. J., Oplekwu, R. I. and Obio, W. A. Anti-Diabetic Potentials of Vernionioside E Saponin; A Biochemical Study. *Natural Volatiles and Essential Oils*. 2021; 8(4): 14234-14254.
16. Obeagu, E. I., Ugwu, O. P. C., Alum, E. U. Poor glycaemic control among diabetic patients; A review on associated factors. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023; 3(1):30-33. <https://nijournals.org/newport-international-journal-of-research-in-medical-sciences-nijrms-volume-3-issue-1-2023/>.
17. Aja, P. M., Ani, O. G., Offor, C. E., Orji, U. O., Alum, E. U. Evaluation of Anti-Diabetic Effect and Liver Enzymes Activity of Ethanol Extract of *Pterocarpussantalinoide*s in Alloxan Induced Diabetic Albino Rats. *Global Journal of Biotechnology & Biochemistry*. 2015;10 (2): 77-83. DOI: 10.5829/idosi.gjbb.2015.10.02.93128.
18. Chen, Y., & Liu, Y. (2023). "Epigenetic Mechanisms and Type 2 Diabetes: Exploring Gene-Environment Interactions." *Frontiers in Endocrinology*, 14, 1124567. doi:10.3389/fendo.2023.1124567
19. Egwu, C. O., Offor, C. E. and Alum, E. U. Anti-diabetic effects of *Buchholziacoriacea* ethanol seed Extract and Vildagliptin on Alloxan-induced diabetic albino Rats. *International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)*. 2017; 6 (6): 1304-1314. www.ijbpas.com. <https://ijbpas.com/pdf/2017/June/1497506120MS%20IJBPAS%202017%204202.pdf>
20. Ugwu O, P. C., Alum, E. U., Obeagu, E. I., Okon, M. B., Aja, P. M., Samson, A. O., Amusa, M. O., Adepoju, A. O. Effect of Ethanol leaf extract of *Chromolaena odorata* on lipid profile of streptozotocin induced diabetic wistar albino rats. *IAA Journal of Biological Sciences*. 2023;10(1):109-117. <https://www.iaajournals.org/wp-content/uploads/2023/03/IAAJB-101109-117-2023-Effect-of-Ethanol-leaf-extract-of-Chromolaena-odorata-on-lipid-profile-of-streptozotocin-induced-diabetic-wistar-albino-rats.docx.pdf>.
21. Ezeani, N. N., Edwin, N., Alum, E. U., Orji, O. U., Ugwu, O. P. C., Effect of Ethanol Leaf Extract of *Ocimum gratissimum* (Scent Leaf) on Lipid Profile of Alloxan-Induced Diabetic Rats. *International Digital Organization for Scientific Research Journal of Experimental Sciences*, 2017; 2 (1): 164-179. www.idosr.org. <https://www.idosr.org/wp-content/uploads/2017/07/IDOSR-JES-21-164-179-2017.-ezeani-2-updated.pdf>
22. Sanchez, J. M., et al. (2023). "Familial Aggregation of Type 2 Diabetes Mellitus: Genetic and Environmental Influences." *Genetics in Medicine*, 25(10), 2451-2462. doi:10.1016/j.gim.2023.05.011
23. Smith, C. S., & Nguyen, T. (2023). "Impact of Genetic Variants on Insulin Sensitivity and Type 2 Diabetes Risk: A Review of Recent Findings." *Current Opinion in Endocrinology, Diabetes, and Obesity*, 30(4), 254-263. doi:10.1097/MED.0000000000000614
24. Li, X., et al. (2023). "CRISPR-Cas9 Gene Editing and Type 2 Diabetes: Potential and Challenges." *Trends in Endocrinology & Metabolism*, 34(8), 685-698. doi:10.1016/j.tem.2023.05.005
25. Ugwu, O.P.C., Kungu, E., Inyangat, R., Obeagu, E. I., Alum, E. U., Okon, M. B., Subbarayan, S. and Sankarapandiyani, V. Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. *INOSR Experimental Sciences*. 2023; 12(2):214-224. <https://doi.org/10.59298/INOSRES/2023/2.17.1000>.
26. Kumar, S., et al. (2023). "Advancements in Polygenic Risk Scores for Type 2 Diabetes Prediction and Management." *Journal of Clinical Endocrinology & Metabolism*, 108(7), 1351-1362. doi:10.1210/clinem/dgad060

27. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Beyond Pregnancy: Understanding the Long Term Implications of Gestational Diabetes Mellitus. INOSR Scientific Research. 2024; 11(1):63-71. <https://doi.org/10.59298/INOSRSR/2024/1.1.16371>
28. Ugwu, O. P. C., Alum, E. U. and Uhama, K. C. (2024). Dual Burden of Diabetes Mellitus and Malaria: Exploring the Role of Phytochemicals and Vitamins in Disease Management. Research Invention Journal of Research in Medical Sciences. 3(2):38-49.

CITE AS: Nyakairu Doreen G. (2024). The Impact of Genetic History on the Risk of Developing Type II Diabetes. Research Output Journal of Biological and Applied Science 4(1):51-57. <https://doi.org/10.59298/ROJBAS/2024/415157>